Valuation: ValiRx plc

Market Cap 11.13L 14.89L 13.06L 12.1L 21.06L 14Cr 21.47L 1.44Cr 56.56L 7Cr 55.93L 54.71L 24Cr P/E 2024
-0.53x
P/E 2025 -0.62x
Enterprise Value 3L 4L 4L 4L 6L 4.14Cr 6L 41.85L 16.41L 2.03Cr 16.23L 15.88L 7.02Cr EV / Sales 2024
2,72,64,249x
EV / Sales 2025 5,41,21,446x
Free-Float
93.4%
Yield 2024 *
-
Yield 2025 -
1 day+2.07%
1 week-4.52%
Current month-7.50%
1 month-20.00%
3 months-52.26%
6 months-61.05%
Current year-55.82%
1 week 0.13
Extreme 0.13
0.16
1 month 0.13
Extreme 0.13
0.19
Current year 0.13
Extreme 0.13
0.48
1 year 0.13
Extreme 0.13
0.85
3 years 0.13
Extreme 0.13
15
5 years 0.13
Extreme 0.13
65
10 years 0.13
Extreme 0.13
1,436.25
Manager TitleAgeSince
Chief Executive Officer 55 12/08/2024
Director of Finance/CFO 81 -
Chief Tech/Sci/R&D Officer - 27/03/2025
Director TitleAgeSince
Director/Board Member 81 01/09/2006
Director/Board Member 62 25/07/2024
Chairman 59 25/07/2024
Date Insider Type Main position Quantity % Market Cap.
04/03Buy

Chief Executive Officer

10,00,000 0.1346%
18/22/18Free

Director

75,000 0.0832%
18/22/18Free

Director

75,000 0.0832%
Change 5-day change 1-year change 3-year change Capi.($)
+2.07%-4.52%-75.33%-97.92% 14.89L
-2.48%-2.22%+55.85%+79.12% 5.35TCr
+0.53%-5.98%+56.67%+128.62% 5.42TCr
-5.60%-2.15%+11.16%+420.46% 2.37TCr
-1.55%-4.11%-20.21%-17.75% 2.28TCr
+2.36%+3.86%+42.80%-6.60% 1.95TCr
-0.25%-0.05%+38.16%-27.79% 1.78TCr
-2.72%-4.04%+187.08%+362.09% 1.6TCr
-1.15%-3.07%+45.33%+654.85% 1.54TCr
-0.81%+0.92%+24.92%+189.61% 1.41TCr
Average -0.96%-2.16%+36.64%+168.47% 2.37TCr
Weighted average by Cap. -1.28%-1.99%+48.21%+163.12%

Financials

2024 2025
Net sales 0.05 0.07 0.06 0.05 0.09 6.37 0.1 0.64 0.25 3.13 0.25 0.24 10.81 0.03 0.04 0.04 0.03 0.06 4.02 0.06 0.41 0.16 1.97 0.16 0.15 6.81
Net income -19.16L -25.63L -22.48L -20.82L -36.23L -25Cr -36.94L -2.48Cr -97.32L -12Cr -96.24L -94.14L -42Cr -22.32L -29.86L -26.19L -24.26L -42.22L -29Cr -43.04L -2.89Cr -1.13Cr -14Cr -1.12Cr -1.1Cr -48Cr
Net Debt -15.44L -20.66L -18.12L -16.78L -29.21L -20Cr -29.77L -2Cr -78.45L -9.71Cr -77.57L -75.88L -34Cr -8L -10.57L -9L -9L -14.95L -10Cr -15.24L -1.02Cr -40.15L -4.97Cr -39.7L -38.83L -17Cr
Logo ValiRx plc
ValiRx Plc is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of science into impactful medicines to improve patient lives. The Company provides the scientific, financial, and commercial framework for enabling rapid translation of science into clinical development. The Company selects and incubates novel drug candidates and guides them through an optimized process of development, from pre-clinical studies to clinical and investor-ready assets. Its product pipeline includes VAL201, VAL301, CLX001 and BC201. VAL201 is a short peptide being studied for the treatment of prostate cancer. VAL201 can prevent cancerous cell proliferation (or growth) without interfering with other functions of the androgen receptor or SRC kinase. CLX001 is a peptide in nanoparticle formulation and is designed for precision destruction of cancer cells to avoid excessive side effects.
Employees
11
Date Price Change Volume
14/26/14 GBX 0.1480 +2.07% 9,62,653
13/26/13 GBX 0.1450 0.00% 4,750
10/26/10 GBX 0.1450 -3.33% 12,73,65,636
09/26/09 GBX 0.1500 -3.23% 1,96,00,569
08/26/08 GBX 0.1550 0.00% 2,265

Annual profits - Rate of surprise